Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia

scientific article

Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1001/JAMA.2015.0894
P932PMC publication ID4377066
P698PubMed publication ID25710658
P5875ResearchGate publication ID272842261

P50authorHeather E WheelerQ30362172
Stephen P HungerQ64215088
Ching-Hon PuiQ66385450
Naomi WinickQ91287117
Meenakshi DevidasQ102141953
P2093author name stringClaudia Wing
Masaaki Komatsu
M Eileen Dolan
Mary V Relling
Shannon M Delaney
Jie J Zheng
William E Evans
Cheng Cheng
Wenjian Yang
Yiping Fan
Mignon L Loh
William L Carroll
Deqing Pei
Xiaomin Lu
Kristine R Crews
Steven W Paugh
Ju Bao
Glen Lew
Barthelemy Diouf
Joseph Robert McCorkle
P2860cites workMaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypesQ24635938
Treating childhood acute lymphoblastic leukemia without cranial irradiationQ24644599
Microtubules as a target for anticancer drugsQ28253993
Clinical and electrophysiological studies in vincristine induced neuropathyQ28373272
Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemiaQ34486506
The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeuticsQ34551578
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemiaQ35015010
CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatmentQ35193958
Ancestry and pharmacogenetics of antileukemic drug toxicityQ35828717
Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approachQ35946327
Treatment of acute lymphoblastic leukemiaQ36366185
Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrationsQ36598611
Clinical ascertainment of health outcomes among adults treated for childhood cancerQ37165621
Pharmacogenomics of serious adverse drug reactions in pediatric oncology.Q37861998
Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemiaQ40635772
Vinorelbine induces apoptosis and caspase-3 (CPP32) expression in leukemia and lymphoma cells: a comparison with vincristineQ40844915
The neuromyopathy of vincristine in man. Clinical, electrophysiological and pathological studiesQ42231739
Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research HospitalQ44976795
Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatmentQ45007602
CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemiaQ47778081
Vincristine pharmacokinetics after repetitive dosing in children.Q52206734
Acute and long-term neurologic complications in children with acute lymphoblastic leukemia.Q53630764
Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia.Q54701330
Acute lymphoblastic leukemiaQ77153499
Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patientsQ80214224
P433issue8
P407language of work or nameEnglishQ1860
P921main subjectleukemiaQ29496
peripheral neuropathyQ945238
lymphoblastic leukemiaQ18553852
P304page(s)815-823
P577publication date2015-02-01
P1433published inThe Journal of the American Medical AssociationQ1470970
P1476titleAssociation of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia
P478volume313

Reverse relations

cites work (P2860)
Q96431587A Metabolomics Approach for Early Prediction of Vincristine-Induced Peripheral Neuropathy
Q100407536A Nuclear Long Non-Coding RNA LINC00618 Accelerates Ferroptosis in a Manner Dependent upon Apoptosis
Q64109892A PRPH splice-donor variant associates with reduced sural nerve amplitude and risk of peripheral neuropathy
Q41367937A systems medicine approach for finding target proteins affecting treatment outcomes in patients with non-Hodgkin lymphoma.
Q38948499Advances and challenges in hereditary cancer pharmacogenetics
Q39459190Advances in adult acute lymphoblastic leukemia therapy
Q39401025An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia
Q53128895Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.
Q53200053Application of stem cell derived neuronal cells to evaluate neurotoxic chemotherapy.
Q92865754Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review
Q46455283CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer
Q26782604Cancer-treatment-induced neurotoxicity--focus on newer treatments
Q92353408Changes in Ecophysiology, Osmolytes, and Secondary Metabolites of the Medicinal Plants of Mentha piperita and Catharanthus roseus Subjected to Drought and Heat Stress
Q28818565Chemotherapy-induced neuropathies-a growing problem for patients and health care providers
Q39293928Chemotherapy-induced peripheral neuropathy: A current review
Q36421901Chemotherapy-induced peripheral neuropathy: Current status and progress
Q26740689Chemotherapy-induced peripheral neuropathy: an update on the current understanding
Q58778223Chemotherapy-induced peripheral neuropathy: evidence from genome-wide association studies and replication within multiple myeloma patients
Q38664595Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics
Q28087637Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
Q47979421Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial
Q38864711Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus
Q98891744Determination of NUDT15 variants by targeted sequencing can identify compound heterozygosity in pediatric acute lymphoblastic leukemia patients
Q38589233Evaluation of inter-batch differences in stem-cell derived neurons.
Q46160844Future cancer research priorities in the USA: a Lancet Oncology Commission
Q90156977Genetic Variants Associated With Vincristine-Induced Peripheral Neuropathy in Two Populations of Children With Acute Lymphoblastic Leukemia
Q33774499Genetics of ancestry-specific risk for relapse in acute lymphoblastic leukemia
Q39262358Genome-Wide Association Studies of Chemotherapeutic Toxicities: Genomics of Inequality
Q89982350Genomic variants of cytarabine sensitivity associated with treatment related mortality in pediatric AML: A report from the Children's Oncology Group
Q91249010Global efforts toward the cure of childhood acute lymphoblastic leukaemia
Q38796874Glutamine for the treatment of vincristine-induced neuropathy in children and adolescents with cancer.
Q80019346Induced pluripotent stem cells for therapy personalization in pediatric patients: Focus on drug-induced adverse events
Q35784497Inherited genetic variation in childhood acute lymphoblastic leukemia
Q37662576Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review.
Q99241249Management of CNS toxicity of chemotherapy and targeted agents: 2020
Q64062172Mechanisms of Chemotherapy-Induced Peripheral Neuropathy
Q47177557Mir-pharmacogenetics of Vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia.
Q48946163Neuroprotective Effect of Matrine in Mouse Model of Vincristine-Induced Neuropathic Pain
Q49201897New model of vincristine-induced neuropathic pain in children: a first step towards prediction and prevention
Q33557148Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy.
Q64269386Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity
Q91634793Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management
Q89453427Outcomes after late bone marrow and very early central nervous system relapse of childhood B-Acute lymphoblastic leukemia: a report from the Children's Oncology Group phase III study AALL0433
Q33744706Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy.
Q36176588Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia
Q91589110Peripheral neuropathy in children and adolescents treated for cancer
Q36117686Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral Neuropathy
Q39796533Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy
Q38419534Pharmacogenetic Markers of Drug Efficacy and Toxicity
Q38895172Pharmacogenetic Predictors of Treatment-Related Toxicity Among Children With Acute Lymphoblastic Leukemia
Q48264298Pharmacogenetic association with neurotoxicity in Hispanic children with acute lymphoblastic leukaemia.
Q64077129Pharmacogenomic and Pharmacotranscriptomic Profiling of Childhood Acute Lymphoblastic Leukemia: Paving the Way to Personalized Treatment
Q28068930Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use
Q38688039Pharmacogenomics in pediatric acute lymphoblastic leukemia: promises and limitations
Q64898627Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy Implicates Pharmacokinetic and Inherited Neuropathy Genes.
Q57074608Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy: Progress Continues
Q52686427Polyneuropathies.
Q47599462Prevention of vincristine-induced peripheral neuropathy by genetic deletion of SARM1 in mice.
Q50200720Questions on asparaginase-associated pancreatitis
Q47552411Risk-reduction and treatment of chemotherapy-induced peripheral neuropathy
Q64922475Severe Neuropathic Pain With Concomitant Administration of Vincristine and Posaconazole.
Q40605146Short-term recovery of chemotherapy-induced peripheral neuropathy after treatment for pediatric non-CNS cancer
Q90463690Somatic and germline genomics in paediatric acute lymphoblastic leukaemia
Q48331843Systematic review of pharmacogenomics and adverse drug reactions in paediatric oncology patients.
Q38739253The role of germline variants in chemotherapy outcome in brain tumors: a systematic review of pharmacogenetic studies.
Q38728572Update on Chemotherapy-Induced Peripheral Neuropathy
Q91361701Variants in vincristine pharmacodynamic genes involved in neurotoxicity at induction phase in the therapy of pediatric acute lymphoblastic leukemia
Q47310338Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia.
Q88715577Vincristine-associated Neuropathy With Antifungal Usage: A Kaiser Northern California Experience
Q38721382Vincristine-induced neuropathy in pediatric patients with acute lymphoblastic leukemia in Oman: Frequent autonomic and more severe cranial nerve involvement.
Q28078232Vincristine-induced peripheral neuropathy in pediatric cancer patients
Q86478393[The second generation sequencing technology and its application in the field of hematologic malignancies]

Search more.